Guozheng Li
Harbin, 150081, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 17, 2025
FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions.
Journal: Journal of advanced research
Published: September 14, 2024
NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.
Journal: Journal of experimental & clinical cancer research : CR
Published: June 22, 2024
Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory.
Journal: Critical reviews in oncology/hematology
Published: August 27, 2022
LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis.
Journal: Cell death & disease
Published: August 24, 2022
Cancer organoids: A platform in basic and translational research.
Journal: Genes & diseases
Published: May 14, 2022
A novel nomogram for decision-making assistance on exemption of axillary lymph node dissection in T1-2 breast cancer with only one sentinel lymph node metastasis.
Journal: Frontiers in oncology
Published: April 20, 2022
A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.
Journal: Journal of immunology research
Published: March 27, 2022
Toward Exempting from Sentinel Lymph Node Biopsy in T1 Breast Cancer Patients: A Retrospective Study.
Journal: Frontiers in surgery
Published: March 06, 2022
Riddle of the Sphinx: Emerging Role of Transfer RNAs in Human Cancer.
Journal: Frontiers in pharmacology
Published: October 14, 2021
Last Updated: 09/26/2026